English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Tuberculosis is a serious threat to public health throughout the world. A series of new 13-n-nonylprotoberberine derivatives was designed, synthesized and evaluated for anti-mycobacterial activity against Mycobacterium tuberculosis strain H37Rv. Several compounds (2, 11a-c, 11g, 13d, 15c) exhibited excellent anti-tubercular activity with an MIC below 1.0μg/mL. Notably, compound 13d showed potential antibacterial effect against both drug-susceptible and multidrug-resistant (MDR) M. tuberculosis with MIC ranges of 0.0625–1.0μg/mL. These results suggest a mode of action different from that of the current anti-mycobacterial drugs rifampicin and isoniazid. Hence, compound 13d is an attractive lead compound for the development of new antitubercular agents

Synthesis and biological evaluation of new 13-n-nonylprotoberberine derivatives as antitubercular agents